Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (54)	5/13/2001 10:59:35 PM
From: Biomaven	Read Replies (1) \| Respond to of 1840

Madharry, This is the terminology I generally see used, although it is not always completely uniform: CR - Complete Response - no clinical sign of cancer remaining. Doesn't mean there won't be a subsequent relapse, so this isn't equivalent to a "cure." PR - Partial Response - more than 50% shrinkage in tumor by some objective measurement Minor Response - Some shrinkage, but less than 50% Stable Disease - tumors not growing. Progressive disease - tumors growing. (These are the failures). As always, you have to interpret any numbers looking carefully at the tumor type, tumor staging and pretreatments. Phase I trials are often in people where everything else has failed, so even stable disease may be seen as something of a success. The general assumption is that results will be much better in earlier stage patients and when a drug is used in combination with other drugs. Peter